Strategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI Vaccines
By Daniella Parra
Brii Biosciences and VBI Vaccines (NASDAQ: VBIV) said they will expand and control of BRII-179 supplies, a late-stage asset for HBV functional cure.
Initially, a $2.5 million promissory note will be issued, eliminating royalty and milestone payments for PreHevbri and upon meeting conditions, the note will increase to $10 million, securing VBI’s IP for BRII-179, Brii Bio said. The company said they plan to become VBI’s commercial supplier for PreHevbrio and PreHevbri.
“As Brii Bio transitions to late-stage development of HBV programs, a global manufacturing strategy becomes critically important. We look forward to working together with the biologics manufacturing experts at the Rehovot site and timely integration of our R&D and manufacturing capabilities,” said Dr. Zhi Hong, Ph.D., Chairman and Chief Executive Officer of Brii Bio.
Contact:
Editor@Executives-edge.com
